Abstract #0928

MRS based biomarkers of IDH1 mutant glioma response to the BAY-1436032 IDH inhibitor

Donghyun Hong¹, Georgios Batsios¹, Pavithra Viswanath¹, Anne Marie Gillespie¹, Russell O Pieper^2,3, Joseph Costello², and Sabrina M Ronen ^1,3

¹Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, ²Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States, ³Brain Tumor Research Center, University of California San Francisco, San Francisco, CA, United States

Mutant IDH1 inhibitor treatment is currently in clinical trials for glioma patients. However, to date, treatment does not result in tumor shrinkage. Therefore, in vivo biomarkers are needed to assess early therapeutic response. Here we treated mutant IDH1-expressing cells with the emerging inhibitor BAY-1436032. Using ¹H MRS we found a significant decrease in 2-hydroxyglutarate that was accompanied by an increase in glutamate and phosphocholine, and using ¹³C MRS we detected a significant increase in glutamate produced from hyperpolarized [1-¹³C]α-ketoglutarate.

This abstract and the presentation materials are available to members only; a login is required.

Join Here